exv4w70



 







    Exhibit 4.70



 



    Certain portions of this Exhibit have been omitted pursuant to a
    request for “Confidential Treatment” under
    Rule 24b-2 of the Securities and Exchange Commission. Such
    portions have been redacted and bracketed in the request and
    appear as [*] in the text of this Exhibit. The omitted
    confidential information has been filed with the Securities and
    Exchange Commission.



 




    AMENDMENT



 



    to the Clinical Trial Agreement between




    Amarin Neuroscience Limited




    and




    University of Rochester



 



    WHEREAS, University of Rochester (“University”) and
    Amarin Neuroscience Limited (“Sponsor”) are currently
    under contract whereby University has undertaken certain
    activities related to a clinical trial research study entitled:
    “A Multi-Center, Double-Blind, Randomized, Parallel Group,
    Placebo-Controlled Trial of Ethyl-EPA
    (Miraxiontm)
    in subjects with Mild to Moderate Huntington’s Disease
    (TREND-HD)”, and



 



    WHEREAS, University and Sponsor have agreed to enter into
    Protocol Amendment Number 2, to extend the open-label protocol
    treatment period and procedures for an additional six months;
    therefore



 



    THIS AMENDMENT does hereby amend the Clinical Trial Agreement
    (hereinafter, the “Agreement”) between Sponsor and
    University, dated March 18, 2005 as follows:



 


			
	 	    1. 
	
    The parties agree that protocol number AN01.01.0011, attached to
    the Agreement as Exhibit A, amended in accordance with
    Protocol Amendment Number 2, attached hereto as
    Exhibit A-1;
    and the Budget for the Study, attached to the Agreement as
    Exhibit C, is fully and completely replaced by the amended
    budget attached hereto as
    Exhibit C-1.

	 
	 	    2. 
	
    The Scope of Work for the Study, attached to the Agreement as
    Exhibit B, shall remain unchanged and shall apply to all
    activities specified in protocol number AN01.01.001, as amended
    herein.




 



    Except as provided herein, all terms and conditions of the
    Agreement, as heretofore amended, remain unchanged.



 


	 	 	 	 	 	 	 
	
    AMARIN NEUROSCIENCE LIMITED
    
	
 
	
    UNIVERSITY OF ROCHESTER
    

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
    BY:
    
	
 
	
    
    
	
 
	
    BY:
    
	
 
	
    

	
 
	
 
	
    

	
 
	
 
	
 
	
    


	
    Name:

    Title:
    
	
 
	
    R. Stewart

    CEO
    
	
 
	
 
	
 
	
    Cheryl N. Williams

    Sr. Research Administrator

    Office of Research & Project Administration
    

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	

    DATE:
    


	
 
	
    8/12/06
    
	
 
	
    DATE:
    
	
 
	
    11/28/06
    



















 







    EXHIBIT
    A-l



 



    Protocol Amendment Number 2













 







    AMENDMENT
    2



 



    VERSION: November 27, 2006



 


 




    [*]













 







    Summary
    of Changes to Protocol ANA01.01.0011

    



 




    Amendment
    #2  November 17, 2006



 




    [*]













 







    University
    of Rochester

    Clinical Trials Coordination Center

    Budget for Miraxion

    Sponsor: Amaria



 




    Exhibit C-1



 




    [*]













 







    University
    of Rochester

    Clinical Trials Coordination Center

    Budget for Miraxion

    Sponsor: Amarin



 




    Exhibit C-1a
    



 



    Payment Schedule for Miraxion (TREND HD) Study —
    Exclusive of Site Payments



 


	 	 	 	 	 
	

    Total Due from Amarin
    


	
 
	
 
	
    $[*]
	
 

	

    Less: Site Payments (and UR
    indirects on payments)
    


	
 
	
 
	
    −$[*]
	
 

	
 
	
 
	
 
	
 
	
 

	

    Total CTCC / HSG Operating Costs
    


	
 
	
 
	
    $[*]
	
 









 


	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    Months

    
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    Actual /

    
	
 
	
 
	
 
	
 
	
    Between

    
	
 

	

    Milestone:


	
 
	
    Percent Due
	
 
	
 
	
    Amount Due
	
 
	
 
	
    Projected Date
	
 
	
    Balance Remaining
	
 
	
 
	
    Payments
	
 

	 

	

    Execution of Contract
    


	
 
	
 
	
    [*]%
	
 
	
 
	
    $
	
    [*]
	
 
	
 
	
 
	
    3/30/2005
	
     Paid
	
 
	
 
	
    $[*]
	
 
	
 
	
 
	
    0
	
 

	

    First Patient Dosed
    


	
 
	
 
	
    [*]%
	
 
	
 
	
    $
	
    [*]
	
 
	
 
	
 
	
    11/29/2005
	
     Paid
	
 
	
 
	
    $[*]
	
 
	
 
	
 
	
    8
	
 

	

    Enrollment 25% Complete
    


	
 
	
 
	
    [*]%
	
 
	
 
	
    $
	
    [*]
	
 
	
 
	
 
	
    3/14/2006
	
     Paid
	
 
	
 
	
    $[*]
	
 
	
 
	
 
	
    4
	
 

	

    Enrollment 75% Complete
    


	
 
	
 
	
    [*]%
	
 
	
 
	
    $
	
    [*]
	
 
	
 
	
 
	
    7/18/2006
	
     Paid
	
 
	
 
	
    $[*]
	
 
	
 
	
 
	
    4
	
 

	

    Data Transfer to
    Amarin —

    All Subjects 6 Mo. Complete
    


	
 
	
 
	
    [*]%
	
 
	
 
	
    $
	
    [*]
	
 
	
 
	
 
	
    1/31/2007
	
 
	
 
	
 
	
    $[*]
	
 
	
 
	
 
	
    6
	
 

	

    Last Subject Enrolled enters OLE
    


	
 
	
 
	
    [*]%
	
 
	
 
	
    $
	
    [*]
	
 
	
 
	
 
	
    7/15/2007
	
 
	
 
	
 
	
    $[*]
	
 
	
 
	
 
	
    6
	
 

	

    Final Data Base to Amarin
    


	
 
	
 
	
    [*]%
	
 
	
 
	
    $
	
    [*]
	
 
	
 
	
 
	
    3/31/2008
	
 
	
 
	
 
	
    $[*]
	
 
	
 
	
 
	
    9
	
 

	

    Final Study Results Available
    


	
 
	
 
	
    [*]%
	
 
	
 
	
    $
	
    [*]
	
 
	
 
	
 
	
    5/31/2008
	
 
	
 
	
 
	
    $[*]
	
 
	
 
	
 
	
    2
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	

    Totals
    


	
 
	
 
	
    100%
	
 
	
 
	
    $
	
    [*]